-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Current Use of Bispecific Antibodies to Treat Multiple Myeloma

Program: Education Program
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Monday, December 11, 2023, 10:30 AM-11:45 AM

Nizar J Bahlis, MD

Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada

Disclosures: Bahlis: Forus: Consultancy, Honoraria; GSK: Consultancy, Other: member of steering committee; BMS: Consultancy, Honoraria; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria, Other: member of steering committee; Karyopharm therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy; Genentech/Roche: Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: IRC member and chair, Research Funding.

See more of: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
See more of: Education Program
Previous Presentation | Next Presentation >>